Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 101.00% | 93.52% | 82.40% | 27.16% | -11.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.00% | 93.52% | 82.40% | 27.16% | -11.42% |
| Cost of Revenue | 57.34% | 49.08% | 38.26% | 5.80% | -16.44% |
| Gross Profit | 146.54% | 143.16% | 135.87% | 52.64% | -5.53% |
| SG&A Expenses | -30.18% | -26.29% | -23.15% | -25.57% | -26.20% |
| Depreciation & Amortization | 2.12% | 10.83% | 19.52% | 26.49% | 37.19% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.42% | -18.02% | -20.29% | -20.01% | -18.37% |
| Operating Income | 21.55% | 22.34% | 23.78% | 21.77% | 18.65% |
| Income Before Tax | 24.64% | 26.09% | 28.11% | 57.59% | 67.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.64% | 26.09% | 28.11% | 57.59% | 67.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.64% | 26.09% | 28.11% | 57.59% | 67.37% |
| EBIT | 21.55% | 22.34% | 23.78% | 21.77% | 18.65% |
| EBITDA | 21.62% | 22.48% | 23.98% | 22.04% | 19.00% |
| EPS Basic | 37.47% | 34.73% | 32.72% | 76.43% | 83.76% |
| Normalized Basic EPS | 35.94% | 32.97% | 31.09% | 47.63% | 54.88% |
| EPS Diluted | 37.47% | 34.73% | 32.72% | 76.43% | 83.76% |
| Normalized Diluted EPS | 35.94% | 32.97% | 31.09% | 47.63% | 54.88% |
| Average Basic Shares Outstanding | 20.27% | 14.28% | 8.30% | 20.59% | 37.47% |
| Average Diluted Shares Outstanding | 20.27% | 14.28% | 8.30% | 20.59% | 37.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
